87 posters,  1 sessions,  81 authors,  78 institutions

ePostersLive® by SciGen® Technologies S.A. All rights reserved.

P4
Dual Antiplatelet Therapy and Surgical Revasculatization: A Survey of Canadian Cardiac Surgeons

Primary tabs

Rate

No votes yet

Statistics

819 reads

Three landmark randomized controlled trials support the use of dual antiplatelet therapy (DAPT), the combination of aspirin and a P2Y12 inhibitor, post-acute coronary syndrome (ACS) regardless of whether they are managed medically, percutaneous or surgically.

  CURE (Yusuf, N Engl J Med. 2001;345:494)

  TRITON–TIMI 38 (Wiviott, N Engl J Med. 2007;257:2001)

  PLATO (Wallentin, N Engl J Med. 2009;361:1045)

 

A recent Focused 2012 Update of the Canadian Cardiovascular Society Guidelines support the use of DAPT for 12 months in patients with ACS after CABG (strong recommendation, moderate-quality evidence; Tanguay, Can J Cardiol. 2013;29:1334)

 

However, in practice, the use of DAPT in patients with ACS undergoing CABG is variable. Two large studies reported 25-26% usage (Krimly, Can J Cardiol. 2011;27:711; Sorensen, J Am Coll Cardiol. 2011;57:1202).

 

To better understand this discrepancy, we developed a survey probe the knowledge and practice patterns of cardiac surgeons on the use of DAPT in patients with ACS undergoing CABG

Enter Poster ID (e.gGoNextPreviousCurrent